Breast cancer radiation showdown: 3D vs internal implants
NCT ID NCT00802711
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared two types of radiation given after breast-conserving surgery for early-stage breast cancer: 3D conformal radiation (external beams) and internal brachytherapy (radioactive material placed in the breast). Only 6 women took part before the trial was stopped early. The goal was to see which method delivers radiation more effectively with fewer side effects, but the small size means no firm conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- radiation therapy (3D conformal or brachytherapy)
- What this could lead to
- If successful, this could help determine which radiation method after breast surgery is better at preventing cancer return while reducing side effects.
- What could go wrong
- This trial was terminated early with only 6 participants, so results are very limited and may not apply to others. The small size means we cannot draw reliable conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
6 people
The number who actually took part.
- Started
-
Oct 2009
- Finished
-
Aug 2011
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 120 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
DISEASE CHARACTERISTICS: * Pathologically proven invasive ductal carcinoma of the breast * Stage I or II disease (pathological tumor size ≤ 3 cm, N0, M0 disease) * No T2 (tumor size \> 3 cm) or T3 disease * No lymph node (L0) or hemangiosis (V0) invasion * Unilateral, unifocal, and unicentric tumor without associated suspicious diffuse microcalcification in the ipsilateral or contralateral breast * No multifocal/multicentric disease * Previously treated with breast-conserving surgery with adequate axillary node management * Negative surgical resection margins for tumor (invasive tumor or ductal carcinoma in situ \[DCIS\]) on histology * Clearly identified primary tumor excision cavity (clips recommended) with a target lumpectomy cavity/whole breast ratio quantifiable and ≤ 25% on the post-operative CT scan * Patients with a lumpectomy cavity/whole breast ratio 25-30% are eligible but will undergo partial breast irradiation using multi-catheter interstitial brachytherapy during study * Breast size amenable to partial breast irradiation (i.e., \> A-cup size) * No other pathological invasive tumor or DCIS * No associated extensive DCIS component (\< 25%) * No associated Paget's disease of the nipple * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No breast implants * No collagen vascular disease * No psychiatric condition or other condition that, in the opinion of the investigator, would preclude study requirements PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior radiotherapy * No concurrent chemotherapy * Sequential chemotherapy allowed * Concurrent hormonal therapy allowed
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Saint Luke's Radiation Oncology Network
Dublin, 6, Ireland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?